Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference
Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that...
Company
Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia
Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...
Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market
Grand Pharmaceutical Group Limited (HKG: 0512) announced a comprehensive strategic commercialization partnership with Siemens Healthineers...
GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted a...
Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its clinical trial application...
Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics
Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a...
Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that...
Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that the U.S....
Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market
Samsung Biologics (KRX: 207940) announced an all-cash bid of 1.46 billion Swiss francs (USD 1.8...
Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients
Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable...
Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis
Hisun Pharmaceutical (SHA: 600267) announced it has entered into an exclusive licensing agreement with EnliTISA...
CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted...
Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals,...
Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has...
Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application...
Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules – Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam...
Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Commission has approved Boey...
GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...
Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution)...
Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...